Apogee therapeutics inc APGE.US 總覽分析
APGE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
APGE 近期報酬表現
2.35%
Apogee therapeutics inc
3.56%
同產業平均
1.47%
S&P500
與 APGE 同產業的標的表現
- APM Aptorum group ltd價值 1 分趨勢 3 分波段 2 分籌碼 -股利 1 分查看更多
APGE 公司資訊
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company's most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4R?. APG279 is for the dual inhibition of OX40L and IL-13.